Humacyte, Inc. - Common Stock, par value $0.0001 per share (HUMA)

CUSIP: 44486Q103

Q2 2026 13F Holders as of 30 Jun 2026

Security type / class
Equity / Common Stock, par value $0.0001 per share
Total 13F shares
17,050
Total 13F value
$13,306
Holder snapshot 5 signals
Share change
-20,768
SEC-reported price per share
$0.78
Number of holders
1
Value change
-$16,204
Number of sells
2
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
269,769,473

Security key

44486Q103

Report period

Q2 2026

Institutions

1

Top holders

2

HUMA full security history Ownership snapshot Full 13F holder table Previous quarter: Q1 2026 Humacyte, Inc. SEC filings Humacyte, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of HUMA - Humacyte, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Fresenius Medical Care AG
Disclosed value leader
FRESENIUS MEDICAL CARE HO...
Comparable rows
15/15
Latest evidence
12 Jun 2026
13D/G 3/4/5 13F Lead comparable stake: 9.5% 13D/G row: Fresenius Medical Care AG Showing 1-6 of 15 holder rows.

Quick read

Fresenius Medical Care AG leads the comparable SEC ownership view at 9.5%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Fresenius Medical Care AG's linked filing trail.
Comparable ownership Top 5
Fresenius Medical Care AG 9.5%
FRESENIUS MEDICAL CARE HOLDINGS I... 6.8%
DAVIDSON KEMPNER CAPITAL MANAGEME... 4.7%
BlackRock, Inc. 4.6%
VANGUARD CAPITAL MANAGEMENT LLC 2.7%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Fresenius Medical Care AG
13D/G
Fresenius Medical Care Holdings, Inc.
13D/G
9.5%
—
18,312,735 shares
 $0 01 Jan 2026
FRESENIUS MEDICAL CARE HOLDINGS INC /NY/
3/4/5 13D/G
Former 10% Shareholder · Fresenius Medical Care Holdings, Inc.
3/4/5 13D/G
6.8%
from 13D/G
$21,792,154
18,312,735 shares
 — 26 Aug 2021
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP
13D/G
13D/G
4.7%
$16,367,453
12,787,073 shares
 $0 12 Jun 2026
BlackRock, Inc.
13F
Company
13F
4.6%
$7,472,696
12,316,955 shares
 — 31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC
13F
Company
13F
2.7%
$4,345,004
7,158,162 shares
 — 31 Mar 2026
ANTIPODES PARTNERS Ltd
13F
Company
13F
2.1%
$3,472,599
5,723,750 shares
 — 31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
1
Shares
17,050
Rows available
1
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 holders
156
Q2 2026 holders
1
Holder diff
-155
Investor Q1 2026 Shares Q2 2026 Shares Share Diff Share Chg % Q1 2026 value Q2 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .